SAB Biotherapeutics Reports 140% Increase in Operating Expenses and $22.5 Million Net Loss for Quarter Ending June 30, 2026

SAB Biotherapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded total operating expenses of $23.4 million for the three months ended June 30, 2026, a 140.2% increase from $9.7 million in the same period last year. This increase was primarily driven by a substantial rise in research and development expenses, which surged to $16.2 million from $7.0 million, reflecting the company's ongoing investment in its lead product candidate, SAB-142, currently in a Phase 2b clinical trial for autoimmune type 1 diabetes (T1D). The net loss for the quarter was $22.5 million, compared to a loss of $10.1 million in the prior year, marking a 122.4% increase.

In terms of financial position, SAB Biotherapeutics reported total assets of $238.2 million as of June 30, 2026, up from $172.8 million at the end of 2025. This growth was attributed to increased cash and cash equivalents, which totaled $8.3 million, alongside a rise in short-term investments to $94.4 million. The company’s accumulated deficit also widened to $152.3 million, reflecting ongoing operational losses as it funds product development and clinical trials. The total stockholders' equity increased to $214.8 million, bolstered by capital raised through recent public offerings.

Strategically, SAB Biotherapeutics has made notable advancements, including the initiation of its pivotal Phase 2b clinical trial, SAFEGUARD, for SAB-142, which aims to modify the treatment paradigm for T1D. The company also expanded its manufacturing capabilities by beginning construction on a second farm facility in South Dakota, intended to enhance production capacity for its therapeutic candidates. Additionally, the company entered into a Master Manufacturing Services Agreement with Emergent BioSolutions for clinical and commercial manufacturing services, which is expected to incur a minimum aggregate spend of $36 million following FDA approval.

Operationally, the company has seen a significant increase in its workforce, with research and development headcount rising to support the advancement of its clinical programs. The total number of common shares outstanding increased to approximately 83.5 million as of June 30, 2026, reflecting the issuance of shares through various financing activities, including a public offering in March 2026 that generated approximately $88.7 million in net proceeds. The company anticipates continued operational losses as it progresses through clinical trials and prepares for potential commercialization of its products.

Looking ahead, SAB Biotherapeutics expects to continue incurring substantial losses as it funds ongoing clinical trials and product development. The company plans to seek additional capital through equity or debt financing to support its long-term objectives. With the current cash reserves and anticipated funding from ongoing and future offerings, the company believes it has sufficient resources to meet its operational needs for at least the next twelve months.